In this episode, host Shikha Jain, MD, speaks with Opyl co-founder Damon Rasheed about using machine learning to better predict clinical trial outcomes, handling ethical concerns surrounding AI in health care and more.

• Welcome to another exciting episode of Oncology Overdrive 0:14
• About Rasheed 0:20
• The interview 0:58
• How did you end up in the AI-powered medicine and clinical trials? 1:48
• What is Opyl, and what is TrialKey? 3:54
• Is TrialKey predominantly based in Australia or is it available outside of Australia as well? 5:34
• Can you explain how machine learning works in order to create these outcomes? 6:11
• How do you see people utilizing this tool in the future based on what you have already seen? 8:30
• How have others received this? What is the feedback you have gotten surrounding what people are excited and concerned about with this technology? 10:50
• Does this type of product take into account the issue of diversity in clinical trials? 13:41
• What’s next for expanding Opyl and TrialKey? 14:27
• What keeps you excited and motivated to continue working in this space? 15:28
• If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 19:35
• How to contact Rasheed 20:16
• Thanks for listening 20:54

Damon Rasheed is a serial entrepreneur recognized for his groundbreaking ventures and deep expertise in machine learning and big data.

We’d love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Rasheed can be reached at opyl.ai or trialkey.ai.

Disclosures: Jain reports no relevant financial disclosures. Rasheed reports TrialKey is powered by Opyl Limited, which is a publicly listed company operating on the ASX.